| Number of patients |
---|---|
Characteristics | nâ=â277, n (%) |
Age, median (range) | median 65 (29â88) |
Gender | |
âMale | 93 (34) |
âFemale | 184 (66) |
Primary disease | |
âBreast cancer | 159 (57) |
âProstate cancer | 26 (9) |
âPancreatic cancer | 13 (5) |
âLung cancer | 12 (4) |
âRCC | 12 (4) |
âGastric cancer | 11 (4) |
âCarcinoma of unknown primary | 8 (3) |
âColorectal cancer | 8 (3) |
âEsophageal cancer | 5 (2) |
âUrothelial cancer | 4 (1) |
âMelanoma | 2 (1) |
âHepatocellular carcinoma | 2 (1) |
âOthers | 15 (5) |
Stage at diagnosis | |
âI | 21 (8) |
âII | 58 (22) |
âIII | 46 (17) |
âIV | 94 (35) |
âUnknown | 46 (17) |
Perioperative chemotherapy | |
âYes | 80 (29) |
âNo | 195 (70) |
âUnknown | 2 (1) |
Metastatic site | |
âLung | 120 (43) |
âLiver | 107 (39) |
âLymph node | 147 (53) |
âBone | 277 (100) |
âBrain | 28 (10) |
âPleura | 23 (8) |
âPeritoneum | 20 (7) |
âAdrenal gland | 17 (6) |
âOthers | 19 (7) |
Prior zoledronic acid treatment | |
âYes | 56 (20) |
âNo | 167 (60) |
âUnknown | 54 (19) |
Number of doses of denosumab | median 10 (1â79) |
More than 45 doses of denosumab | 16 (5) |